A Phase 3 interventional study of Pralsetinib and Carboplatin in RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm and Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Terminated at 74 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 54th largest by enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2020, is one of 48 in phase 3, and was the 150th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 16 more countries
Ages 18+
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 66 · Phase 3 50 · Phase 4 10
First in 2001; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 136 across the 142 interventional studies, 289 across the 37 observational. Of the 161 that completed or were terminated, 96 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05170204Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | 2027-01-19 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT04302025Genentech, Inc.A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | 2026-11-30 |
| NCT04140500Hoffmann-La RocheDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | 2027-06-30 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 223 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant should not have received any prior anticancer therapy for metastatic disease.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Experimental Arm will receive Pralsetinib
Drug: Pralsetinib
Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology) Nonsquamous histology * Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance. * Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance. Squamous histology * Carboplatin or cisplatin / gemcitabine * Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab
Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Pembrolizumab · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-Paclitaxel
Administered orally
Also known as: BLU-667
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)
PFS was defined as the time from randomization to the date of first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (K-M) method was used to estimate median PFS. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Up to approximately 50 months
Arm A vs Arm B: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.
Time frame: Up to approximately 50 months
Arm A vs Arm B: Overall Survival (OS)
OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: From randomization to death (up to approximately 50 months)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Time frame: Up to approximately 50 months
Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
ECOG is a 6-point scale (0-5) used to assess participants functional status, where, 0= Fully active, able to carry on all pre-disease performance without restriction; 1= restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2= ambulatory \& capable of all self-care but unable to carry out any work activities. Up \& about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5= dead.
Time frame: Baseline up to 50 months
Arm A vs Arm B: Duration of Response (DOR)
DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate median DOR. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Up to approximately 50 months
Arm A vs Arm B: Clinical Benefit Rate (CBR)
CBR was defined as the percentage of participants who experienced the best response of stable disease (SD) with a minimum duration of 6 months, a CR, or a PR, as assessed by investigator with use of RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.
Time frame: Up to approximately 50 months
Arm A vs Arm B: Disease Control Rate (DCR)
DCR was defined as the percentage of participants who experienced the best response of CR, or PR, or SD, as assessed by investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.
Time frame: Up to approximately 50 months
A total of 223 participants with rearranged during transfection (RET) fusion-positive metastatic non-small cell lung cancer (NSCLC) took part in the study at 74 investigative sites across 22 countries from 24 July 2020 to 27 January 2025. The study consists of a treatment period and a crossover period.
| Milestone | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| Started | 113 | 110 | 0 |
| Safety-evaluable population | 104 | 108 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 113 | 110 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 |
| Withdrew: Death | 26 | 29 | 0 |
| Withdrew: Informed consent withdrawn | 19 | 8 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 |
| Withdrew: Reason not specified | 9 | 6 | 0 |
| Withdrew: Progressive disease | 3 | 10 | 0 |
| Withdrew: Study terminated by sponsor | 52 | 53 | 0 |
| Milestone | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| Started | 0 | 0 | 38 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 38 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 8 |
| Withdrew: Informed consent withdrawn | 0 | 0 | 2 |
| Withdrew: Reason not specified | 0 | 0 | 3 |
| Withdrew: Progressive disease | 0 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 21 |
PFS was defined as the time from randomization to the date of first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (K-M) method was used to estimate median PFS. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) | 9.0 (7.1 to 11.5) | 18.7 (11.1 to 25.2) |
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.
| percentage of participants | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Objective Response Rate (ORR) | 41.6 (32.40 to 51.24) | 65.5 (55.79 to 74.26) |
OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Overall Survival (OS) | 39.8 (39.8 to NA) | NA (29.6 to NA) |
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
| Participants | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| AEs | 104 | 108 | 38 |
| SAEs | 38 | 67 | 22 |
ECOG is a 6-point scale (0-5) used to assess participants functional status, where, 0= Fully active, able to carry on all pre-disease performance without restriction; 1= restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2= ambulatory \& capable of all self-care but unable to carry out any work activities. Up \& about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5= dead.
| Participants | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| Baseline ECOG Score 0: Post-baseline Score 0 | 14 | 18 | 3 |
| Baseline ECOG Score 0: Post-baseline Score 1 | 28 | 22 | 7 |
| Baseline ECOG Score 0: Post-baseline Score 2 | 0 | 3 | 2 |
| Baseline ECOG Score 0: Post-baseline Score 3 | 0 | 1 | 1 |
| Baseline ECOG Score 0: Post-baseline ECOG Missing | 0 | 0 | 1 |
| Baseline ECOG Score 1: Post-baseline Score 0 | 1 | 2 | 0 |
| Baseline ECOG Score 1: Post-baseline ECOG 1 | 46 | 44 | 17 |
| Baseline ECOG Score 1: Post-baseline ECOG 2 | 10 | 11 | 4 |
| Baseline ECOG Score 1: Post-baseline ECOG 3 | 1 | 3 | 1 |
| Baseline ECOG Score 1: Post-baseline ECOG 4 | 0 | 2 | 1 |
| Baseline ECOG Score 1: Post-baseline ECOG Missing | 4 | 2 | 0 |
| Baseline ECOG Score 2: Post-baseline ECOG Missing | 0 | 0 | 1 |
DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate median DOR. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Duration of Response (DOR) | 9.7 (7.6 to 15.9) | 20.6 (17.2 to 31.8) |
CBR was defined as the percentage of participants who experienced the best response of stable disease (SD) with a minimum duration of 6 months, a CR, or a PR, as assessed by investigator with use of RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.
| percentage of participants | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Clinical Benefit Rate (CBR) | 58.4 (48.76 to 67.60) | 74.5 (65.35 to 82.37) |
DCR was defined as the percentage of participants who experienced the best response of CR, or PR, or SD, as assessed by investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.
| percentage of participants | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib |
|---|---|---|
| Arm A vs Arm B: Disease Control Rate (DCR) | 79.6 (71.04 to 86.64) | 88.2 (80.64 to 93.55) |
Collected over Up to approximately 50 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Treatment Period- SOC | 27/113 (23.9%) | 38/104 (36.5%) | 103/104 (99%) |
| Arm B: Treatment Period- Pralsetinib | 33/110 (30%) | 67/108 (62%) | 106/108 (98.1%) |
| Arm C: Crossover Period- Pralsetinib | 8/38 (21.1%) | 22/38 (57.9%) | 38/38 (100%) |
| Event | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/104 | 16/108 | 3/38 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/104 | 1/108 | 4/38 |
| PyrexiaGeneral disorders | 0/104 | 7/108 | 0/38 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/104 | 0/108 | 2/38 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/104 | 5/108 | 2/38 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/104 | 2/108 | 2/38 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/104 | 1/108 | 0/38 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/104 | 4/108 | 0/38 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/104 | 4/108 | 1/38 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/104 | 2/108 | 0/38 |
| Event | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Arm C: Crossover Period- Pralsetinib |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 47/104 | 52/108 | 10/38 |
| NauseaGastrointestinal disorders | 48/104 | 20/108 | 5/38 |
| ConstipationGastrointestinal disorders | 30/104 | 47/108 | 12/38 |
| Aspartate aminotransferase increasedInvestigations | 19/104 | 45/108 | 8/38 |
| DiarrhoeaGastrointestinal disorders | 22/104 | 44/108 | 4/38 |
| AstheniaGeneral disorders | 38/104 | 27/108 | 7/38 |
| Alanine aminotransferase increasedInvestigations | 22/104 | 39/108 | 7/38 |
| HypertensionVascular disorders | 4/104 | 32/108 | 12/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/104 | 29/108 | 8/38 |
| NeutropeniaBlood and lymphatic system disorders | 19/104 | 27/108 | 7/38 |
Intent-to-Treat (ITT) population included all randomized participants whether or not the assigned study treatment is received.
| Age, Continuous(years) | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Total |
|---|---|---|---|
| Mean | 62.3 ± 12.3 | 61.6 ± 11.1 | 61.9 ± 11.7 |
| Sex: Female, Male(Participants) | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Total |
|---|---|---|---|
| Female | 64 | 53 | 117 |
| Male | 49 | 57 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 18 | 37 |
| Not Hispanic or Latino | 77 | 82 | 159 |
| Unknown or Not Reported | 17 | 10 | 27 |
| Race/Ethnicity, Customized(Participants) | Arm A: Treatment Period- SOC | Arm B: Treatment Period- Pralsetinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 9 | 16 |
| Asian | 22 | 21 | 43 |
| Black or African American | 2 | 2 | 4 |
| White | 65 | 68 | 133 |
| Other | 3 | 1 | 4 |
| Unknown | 0 | 4 | 4 |
| Not Reported | 14 | 5 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jul 2020 to primary completion in Jan 2025, 54 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pralsetinib
Carcinoma, Non-Small-Cell Lung →